India, Nov. 20 -- Friday, Annovis Bio, Inc. (ANVS) announced that the U.S. Food and Drug Administration (FDA) has agreed to its Integrated Summary of Safety (ISS) plan for buntanetap, an investigational once-daily oral therapy being developed for Alzheimer's disease (AD) and Parkinson's disease (PD).

The agreement allows Annovis to combine safety data from its Alzheimer's and Parkinson's clinical programs into a single database to support its planned New Drug Application (NDA).

The FDA also agreed with the proposed approach for integrating the pooled data using standardized analysis datasets and provided recommendations on the statistical methods.

The pooled safety analysis will include four clinical studies: a completed Phase 3 trial in...